Published on 20 Jun 2024 on Simply Wall St. · via Yahoo Finance
ADC Therapeutics SA (NYSE:ADCT) Shares Could Be 50% Below Their Intrinsic Value...
Key Insights
Using the 2 Stage Free Cash Flow to Equity, ADC Therapeutics fair value estimate is US$6.30ADC Therapeutics is estimated to be 50% undervalued based on current share price of US$3.16 The US$10.00 analyst price target for ADCT is 59% more than our estimate of fair value
How far off is ADC Therapeutics SA (NYSE:ADCT) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to today's value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.